ASCENTAGE-B (06855) issues restricted stock units and stock options.

ASCENTAGE-B (06855) announces that as of the date of this announcement, a total of 696,300 restricted share units (2022 RSUs) have been granted to three selected individuals under the 2022 Restricted Share Unit Plan. This is equivalent to 696,300 shares of stock (2022 RSUs further granted), with 393,800 RSUs granted to Dr. Yang Dajun, an executive director and CEO of the company; 283,900 RSUs granted to Dr. Zhai Yifan, the chief medical officer and major shareholder of the company; and 18,600 RSUs granted to another senior executive of the company. As of the date of this announcement, in accordance with the terms of the First Public Offer Share Purchase Option Plan, an additional 513,200 share options (2022 Share Options) have been granted to Dr. Yang and Dr. Zhai, giving them the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise of these options. However, the exercise of these options is subject to acceptance by Dr. Yang and Dr. Zhai, with 298,200 share options granted to Dr. Yang and 215,000 share options granted to Dr. Zhai.